Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling

• Main Authors: Xavier J. H. Pepin (Author), Scott M. Hynes (Author), Hamim Zahir (Author), Deborah Walker (Author), Lois Q. Semmens (Author), Sandra Suarez‐Sharp (Author)
• Format: Book
• Published: Wiley, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Omaveloxolone is a nuclear factor (erythroid‐derived 2)‐like 2 activator approved in the United States and the European Union for the treatment of patients with Friedreich ataxia aged ≥16 years, with a recommended dosage of 150 mg orally once daily on an empty stomach. The effect of the US...